Post Content
Johnson & Johnson (NYSE:JNJ) is one of the
10 Best Performing Dow Stocks So Far in 2026.
On April 14, 2026, Reuters reported that Johnson & Johnson (NYSE:JNJ) topped first-quarter earnings projections and raised its full-year forecast. The firm reported revenue of $24.1 billion, above forecasts of $23.6 billion. The adjusted earnings per share were $2.70 as compared to $2.66 projected. Strong demand for Darzalex and Tremfya offset a significant dip in Stelara sales.
Stelara sales fell over 60% year on year to $656 million when the patent expired. Tremfya’s quarterly sales were $1.6 billion, beating the $1.2 billion prediction. Darzalex delivered $4 billion, exceeding the $3.4 billion expectations. According to CFO Joseph Wolk, patients have shifted away from biosimilars in favor of other treatments.
The corporation announced early success with Icotyde, pointing out approximately 1,500 prescriptions within weeks of launch. Johnson & Johnson (NYSE:JNJ) raised its sales forecast for 2026 to a midpoint of $100.8 billion and its adjusted EPS guidance to $11.55. Medical device sales rose by 7.7% to $8.6 billion, matching expectations.
Trong Nguyen / Shutterstock.com
Johnson & Johnson (NYSE:JNJ) is a holding corporation that researches, develops, manufactures, and sells healthcare products. It operates through two segments: Innovative Medicine and MedTech.
While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.